ScarX Therapeutics is a pre-clinical stage biotechnology company focused on the development of a novel therapeutic (MI-001) as the first topical, patient-administered, prescription medication for the prophylaxis of dermal scarring in post-surgical wound closures.
Each year there are approximately 240 million surgeries worldwide that have the potential of producing unwanted scarring of skin. For many, scars can be uncomfortable, disfiguring, restrict joint mobility, and can compromise an individuals self esteem. Currently there is no clinically proven therapeutic for the prevention or reduction of dermal scarring.
The discovery of MI-001 as an anti-scarring agent is the result of over 15 years of research conducted by Dr. Benjamin Alman, a Senior Scientist and Head of Orthopaedic Surgery at the Toronto Hospital for Sick Children. Dr. Almanʼs research confirmed that β-catenin mediates scar tissue formation and demonstrated that wounds where fibroblasts have elevated levels of β-catenin resulted in excessive scarring. Further, drawing from a library of known active pharmaceutical ingredients (API), was able to identify a high potential target for β-catenin synthesis inhibition. ScarX has successfully formulated and tested a proprietary topical cream preparation using this API (MI-001), which is now moving forward in our development program. Pre-clinical in vitro and in vivo studies have confirmed that MI-001 applied topically to post wound closures promotes healthy tissue healing and significantly reduces scarring.
"…he appears to have hit upon a discovery sought since ancient times: how to dramatically reduce scar formation."
The company's vision is to provide a meaningful quality-of-life benefit to patients who wish to prevent or reduce the formation of restrictive, disfiguring, or cosmetically unattractive dermal scars.